NSCLC has a variety of genetic and environmental causes and various therapies, however the RET fusion mutation, which accounts for 1 to 2% of the causes of NSCLC, is known to be a malignant cancer with no approved treatment available to date. Cancer develops when RET gene, which should be functioning normally, shifts and binds to genes such as CCDC6, KIF5B, showing abnormally high activity.
Currently there is not any approved drug for RET fusion mutation non-small cell lung cancer except for radiation therapy or chemotherapy that usually accompany several adverse effects. A novel therapy for RET fusion mutation will be a hope for many patients with the mutation.
In CCDC6-RET fusion mutation xenograft mouse model, the control group showed sustained growth of cancer cells, whereas in VRN06-treated group showed suspension in growth of cancer cells. In KIF5B-RET fusion mutations xenograft mouse model as well, VRN 06-treated group showed suspension in growth of cancer cells. This means VRN06 has the potential to specifically and consistently treat NSCLC caused by RET fusion.
VRN06 plans o begin nonclinical toxicity study in various animals in 2H 2019, and will initiate phase 1 clinical trials in patients with terminal lung cancer within 2H 2020 in Korea.
Voronoi is working with renowned top service providing CROs including Knotus, Wuxi, and Champions Oncology to successfully develop VRN06 program.